PCI Biotech presenterer resultater fra gallekreftstudie

Publisert 17. oktober 2016
Abstract fra fase 1-studien blir presentert som «late-breaking news» under United European Gastroenterologo Week (UEGW) i dag.
PCI Biotech: Results from the bile duct cancer study will be presented as late-breaking news at United European Gastroenterology Week
Oslo, October 17, 2016 – PCI Biotech today announced that an abstract with results from the phase I bile duct cancer study has been selected for oral presentation as late-breaking news at the United European Gastroenterology (UEG) Week.
The results will be presented by Dr. Alexander Dechêne, University Hospital Essen, Germany, who is one of the investigators in the phase I study.  The presentation «Phase I study with photochemical Internalisation (PCI) – a novel technology for treatment of perihilar cholangiocarcinoma» will be held today at 15:00 local time in room M at the Austria Center Vienna (ACV), Vienna, Austria. The presentation will be made available on PCI Biotech’s home page.
About United European Gastroenterology (UEG)
United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive health. The member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAC (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAC utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.